论文部分内容阅读
目的 临床验证国内首创的新一代化疗栓塞剂甲氨蝶呤明胶微球 (MTX- m s)对中晚期原发性肝癌 (PHC)的疗效。方法 将 6 3例肝癌病人随机分成两组 ,分别用 MTX-ms和碘油加明胶海绵颗粒结合化疗药物经超选择性肝动脉插管进行化疗栓塞。根据肿瘤的血管造影表现、坏死面积、大小和血清 AFP值的变化比较两种方法的疗效。结果 经 1～ 3次治疗后两组病人的肿瘤血管明显减少 ,肿瘤体积显著缩小 ,AFP值明显下降。各项疗效指标显示 MTX- m s组在某些方面优于常规治疗组 ,但统计学上无显著性差异。结论 MTX- ms具有使用方便、用量小、末梢栓塞作用强和价廉等优点 ,对肝癌的疗效与目前的常规化疗栓塞相当
Objective To clinically verify the efficacy of the new generation of chemoembolization agent methotrexate gelatin microspheres (MTX-MS) for the treatment of advanced primary liver cancer (PHC). Methods Sixty-three patients with HCC were randomly divided into two groups. MTX-ms and lipiodol plus gelatin sponge particles combined with chemotherapeutic agents were used to perform chemotherapy embolization with superselective hepatic artery catheterization. The efficacy of the two methods was compared based on the angiographic appearance, necrosis area, size, and serum AFP values of the tumor. Results After 1 or 3 treatments, the tumor vessels in the two groups were significantly reduced, the tumor volume was significantly reduced, and the AFP value was significantly decreased. The efficacy indicators showed that the MTX-MS group was superior to the conventional treatment group in some aspects, but there was no statistically significant difference. Conclusions MTX-ms has the advantages of convenient use, small dosage, strong peripheral embolization, and low cost. The efficacy of HTX-ms is comparable to that of current conventional chemoembolization.